Trial · NCT01999972
Results by group1,108
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 1,108
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Dose-Escalation Part: Number of Participants With Dose-Limiting Toxicities (DLTs) | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | 0 | Participants | ||
| Dose-Escalation Part: Number of Participants With Dose-Limiting Toxicities (DLTs) | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | 0 | Participants | ||
| Dose-Escalation Part: Number of Participants With Dose-Limiting Toxicities (DLTs) | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | 0 | Participants | ||
| Dose-Escalation Part: Number of Participants With Dose-Limiting Toxicities (DLTs) | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | 0 | Participants | ||
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | AEs | 5 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | AEs | 3 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | AEs | 3 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | AEs | 10 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | AEs | 21 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg | AEs | 7 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | SAEs | 2 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | SAEs | 2 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | SAEs | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | SAEs | 5 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Expansion Part: Cohort 1 Crizotinib 250 mg+Axitinib 5 mg | SAEs | 8 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Expansion Part: Cohort 2 Crizotinib 250 mg+Axitinib 5 mg | SAEs | 3 | Participants | |
| Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Escalation Part: Crizotinib 200mg+Axitinib 3mg | AEs | 4 | Participants | |
| Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Escalation Part: Crizotinib 250mg+Axitinib 3mg | AEs | 3 | Participants | |
| Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Escalation Part: Crizotinib 200 mg+Axitinib 5 mg | AEs | 3 | Participants | |
| Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Dose Escalation Part: Crizotinib 250 mg+Axitinib 5 mg | AEs | 9 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01999972/results